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Abstract : Glioblastoma （GBM） is difcult to completely cure by surgical treatment 
alone, and it is generally treated with a combination of surgery, radiotherapy, and 
chemotherapy.  However, GBM is resistant to radiotherapy and chemotherapy, and 
complete cure cannot be achieved.  Cancer stem cells （CSC） and survivin, which 
inhibit apoptosis, are considered as factors underlying tumor recurrence and the 
radiation- and drug-resistance of these tumors.  We analyzed CSC and survivin 
expression in surgically excised specimens of malignant brain tumors to establish 
the relationships between the grades and CSC and survivin expression and between 
MIB-1（Ki-67） expression and resistance.  No relationship was noted between the 
grades and CSC or survivin expression, or between MIB-1 and CSC expression or 
between Grade 3 and 4 MIB-1 and survivin expression, although a correlation was 
noted between MIB-1 and survivin expression in Grade Ⅱ tumors.  These ndings 
suggested that CSC are consistently contained in tumor tissue at a specific rate 
regardless of the histological grade, and the apoptosis of cells with low-level prolif-
erative and cell cycling activities does not occur because these cells do not respond 
to chemotherapy or radiation, being resistant to treatment.
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Introduction
　Among primary brain tumors, highly malignant, high-grade glioblastoma （59％） and 
medulloblastoma （62％） show a high incidence in males and frequently develop in the 40～
50s age group.  Glioblastoma （GBM） and medulloblastoma of grade Ⅳ, based on the WHO 
classification, grow rapidly and are fatal if untreated.  Histologically, these brain malignancies 
show abundant cell division and necrosis, rapidly infiltrate the surrounding tissue, and disseminate 
to the meninx1）.  GBM and medulloblastoma are therefore highly malignant tumors associated 
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with a poor prognosis and survival time shorter than 1 year.  In addition, the therapeutic 
outcomes for patients with these tumors have not markedly improved over several decades.  
　Glioblastoma consists of mature glioma, and reportedly, most are dedifferentiated atypical 
astrocytoma2） REF.  However, undifferentiated pluripotent cells with a self-replicating ability 
were recently reported in glioblastoma tissue REF 3）.  Such cells, termed cancer stem cells 
（CSC）, were also identified in acute myelogenous leukemia4）, breast cancer 5）, and other brain 
tumors6-9）, and CSC-targeting treatment methods are now being investigated.  CSC are in the 
G0 phase of the cell cycle, present in tissue as a stem cell-specific side population （SP cells） 
in various cancer tissues and cancer cell lines including GBM, and have tumor-forming and 
treatment-resistant properties7，10）.  Recent investigations have thus focused on developing new 
anticancer drugs effective for CSC, a radiosensitizer application method aiming at increasing the 
effect of radiotherapy on CSC, and a CSC-targeting treatment using immunocytes11，12）.  Tumor 
progression in glioblastoma was also effectively inhibited by an anti-angiogenic treatment that 
blocks the vascular niche or portal for CSC and the surrounding tumor cells.  Those studies also 
correlated both CSC expression and survival time with the clinical outcomes of patients with 
oligodendrocyte tumors, revealing CSC to be a useful prognostic factor13，14）.  
　Survivin belongs to the inhibitors of the apoptosis （IAP） family, which all inhibit apoptosis 
by inhibiting caspase15）.  It is strongly expressed in embryonic cells, but it is expressed only in 
limited organs in adults, including the testis and thymus.  Survivin is undetectable in adult tissue, 
but its overexpression was recently reported in human malignant tumors of the large intestine, 
breast, stomach, esophagus, liver, and ovary16）.  Patients overexpressing the survivin gene in their 
cancer cells have a poor prognosis, and anti-survivin antibody production occurs in the blood 
of cancer patients REF 17，18）.  Furthermore, antisense inhibition of survivin gene expression in 
cancer cells induced apoptosis, and together, these findings prompted investigation of survivin as 
an immunotherapy target19）.  However, there is no reported association with either the growth 
of malignant brain tumors or the WHO grade with CSC and survivin expression pattern.  In 
this study, we analyzed the association between WHO grade and CSC survivin expression to 
investigate the important relationship between WHO grade and treatment resistance.  
Material and Methods
Subjects
　In this study we investigated specimens surgically excised from 70 patients with malignant 
brain tumor from 1987 to 2000.  The group comprised 32 patients with grade 2 astrocytoma, 4 
patients with grade 3 astrocytoma, and 34 patients with grade 4 glioblastoma （Table 1）.
Statistical analysis
　Data were tested for significance using ANOVA and Bonferroni.  Results were considered 
significant with a P value ＜ 0.05.
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Fluorescent immunohistochemistry
　Eighty-two sections in total from the specimens were deparaffinized, and then incubated in 
0.3％ H2O2 for 5 min to remove endogenous peroxidase.  The sections were then incubated 
in non-specific blocking reagent （X0909, Dako, Glostrup, DK） for 5 min to block nonspecific 
staining.  Sections were first incubated with anti-PROM1 primary antibody （1:100, Abnova, 
Taipei, Taiwan） for 1 hour at room temperature, and a secondary, TRIC-conjugated anti-rabbit 
IgG （A21428, Life Technologies, USA） in a humid chamber at 37℃ for 30 min.  Sequentially, 
sections were incubated with anti-survivin （1:100, M2624, Dako） and anti- Ki-67（MIB-1） 
（1:100, M0722, Dako） primary antibodies at 37℃ for 1 hour, and then a secondary antibody 
FITC-conjugated anti-mouse lgG （A11001, Life Technologies, USA） for 30 min.  Sections were 
systematically counterstained with bisbenzimide H33342 （Hoechst 33342）, and images were 
captured on a confocal microscope （Meta Xpress Image Analysis）.
Results
Clinicopathological characteristics of the patients
　Table 1 lists the clinicopathological characteristics of malignant brain tumors in the 70 
patients.  To confirm the relationship between malignancy grade and proliferative ability, 
immunohistochemistry （IHC） analysis was performed using fluorescence labeled antibody 
detection.  Typical morphological characteristics of the malignant brain tumors were examined by 
HE staining （Fig. 1A, B, C）.
Results of immunostaining 
　MIB-1 protein is used as an index of prognosis in patients with malignant tumors because it 
marks cells undergoing nuclear division.  The MIB-1-immunopositive rate was 3.72％ in Grade Ⅱ 
astrocytoma, 4.57％ in Grade Ⅲ anaplastic astrocytoma, and 8.8％ in Grade Ⅳ glioblastoma, thus 
the proliferative ability of the cells increased with the histological grade （Fig. 2A）.
　To detect undifferentiated CSC, we employed IHC using the anti-PROM antibody, 
Table 1.  Patient backgrounds and gene expressions
Histological grade （WHO） Grade Ⅱ Grade Ⅲ Grade Ⅳ
Patients 32 4 34
Sex （male / female） 11 / 21 4 / 0 14 / 20
Age, medium （range）
40
（9-73）
39.5
（30-50）
54.5
（11-71）
MIB-1-positive （％） 3.72 4.57 8.8
PROM-positive （％） 0.94 0.58 0.89
Survivin-positive （％） 2.00 0.59 1.99
All values represent mean ± SD （range）
WHO, World Health Organization
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and confirmed the localization of CSC in the tumor core （Fig. 1G, H, I）.  The PROM-
immunopositive rate was 0.94％ in Grade Ⅱ astrocytoma, 0.58％ in Grade Ⅲ anaplastic 
astrocytoma, and 0.89％ in Grade Ⅳ glioblastoma, showing no significant association between 
undifferentiated CSC rate and grade （Fig. 2B）.
　We then localized survivin to the tumor cell cytoplasm （Fig. 1J, K, L）.  The survivin-
immunopositive rate was 2.00％ in Grade Ⅱ astrocytoma, 0.59％ in Grade Ⅲ anaplastic 
astrocytoma, and 1.99％ in Grade Ⅳ glioblastoma, again showing no significant difference in 
surviving expression among the tumor grades （Fig. 2C）.  
Comparison of proliferative ability with PROM and survivin in each grade
　PROM and survivin expressions relative to MIB-1 （proliferative ability index） were analyzed 
Fig. 1.  MIB-1, PROM, and survivin expression in human glioma.
（A-C） Hematoxylin / eosin（HE）-stained sections of Grade Ⅱ（A）, Grade Ⅲ（B）, and Grade Ⅳ 
malignancies（C）. MIB-1 expression was detected by immunohistochemistry in Grade Ⅱ（D）, Grade 
Ⅲ（E）, and Grade Ⅳ malignancies（F）. PROM expression was detected in Grade Ⅱ（G）, Grade Ⅲ
（H）, and Grade Ⅳ malignancies（I）. Survivin expression was detected in Grade Ⅱ（J）, Grade Ⅲ（K）, 
and Grade Ⅳ malignancies（L）.
Magnification×200.
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in each grade.  No significant correlation was noted between Grade Ⅱ MIB-1 and Grade Ⅱ 
PROM expression, between Grade Ⅲ MIB-1 and Grade Ⅲ PROM expression, or between 
Grade Ⅳ MIB-1 and Grade Ⅳ PROM expression.  However, there was a significant correlation 
between Grade Ⅱ MIB-1 and Grade Ⅱ survivin expression, but not between Grade Ⅲ MIB-1 
and Grade Ⅲ survivin expression or between Grade Ⅳ MIB-1 and Grade Ⅳ survivin expression 
Fig. 2.  Significance of differences in MIB-1, PROM, and survivin expression 
among tumor grades. 
（A） A significant difference was noted in MIB-1 expression between 
Grades 2 and 4 malignancies, but no significant differences were noted 
in （B） PROM or （C） survivin expression （ANOVA and Bonferroni 
test）.
Table 2.  Immunohistochemical analysis of MIB-1 and 
survivin expression in glioma
Histological grade 
（WHO）
MIB-1（％） Survivin P value
Ⅱ 3.72 2.00 0.001
Ⅲ 4.57 0.59 0.21
Ⅳ 8.8 1.99 0.21
Survivin expression of the MIB-1 was significantly different 
among the tumor grades （P＜ 0.001）.
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（Table 2）.  
Discussion 
　Malignant brain tumors show strong resistance to postoperative chemotherapy and radiotherapy, 
and a correlation between CSC numbers in the tumor and the resistance mechanism has 
been suggested as a cause.  CSC-induced resistance is considered to derive from the cells’ 
self-replicating and proliferative abilities and drug-eliminating ATP binding cassette （ABC） 
transporters.  Survivin belongs to the inhibitor of apoptosis （IAP） family, and mediates cellular 
resistance by inhibiting cell death.  
　The present study found no significant difference in MIB-1expression between Grade Ⅱ and Ⅲ 
malignant brain tumors, but a significantly higher immunopositivity for this protein was noted 
in Grade Ⅳ tumors.  However, no significant difference was noted in PROM expression among 
Grades Ⅱ, Ⅲ, and Ⅳ.  The relationship between MIB-1 and PROM was analyzed in each 
grade, but no significance was detected, showing that CSC accounted for a constant ratio of cells 
regardless of the grade of malignant brain tumor.  No significant correlation was noted between 
Grade Ⅱ MIB-1 and Grade Ⅱ PROM expression, between Grade Ⅲ MIB-1 and Grade Ⅲ 
PROM expression, or between Grade Ⅳ MIB-1 and Grade Ⅳ PROM expression.  Tumor cells 
with a high proliferation rate showing active cell cycling and CSC constantly arrested in the G0 
phase may be not related to the grading, which is based solely on cells in the growth phase, and 
thus CSC and resistance due to survivin are not taken into consideration.  This study suggested 
that treatment-resistant CSC in the G0 phase are constantly present at a specific rate in 
preoperative malignant brain tumors before radiotherapy and chemotherapy.  CSC are maintained 
in the G0 phase （resting phase）, with the number, division, and resting phase of CSC controlled 
through interactions with the environment （tissue microenvironment and cellular niche） around 
CSC.  The microenvironment called a niche for CSC to carry out the work as a stem cell is 
required.  In addition, CSC have an inherent self-replicating ability, and we previously reported 
that CSC in the G0 phase differentiated and proliferated when cultured malignant brain tumor 
cells were irradiated at a high dose20，21）, suggesting that, when radiation and chemotherapy are 
applied as postoperative treatment, it is important to set the treatment target at CSC and reduce 
the treatment resistance of CSC in the malignant brain tumor by destroying the CSC growth-
promoting niche （micro） environment, which in turn induces the differentiation of CSC in the 
G0 phase, and inhibits molecules necessary for self-replication.  
　Survivin is an IAP family protein, all of which contain the anti-apoptosis action-determining 
baculovirus IAP repeat （BIR） domain22）.  Two splice variants （survivin2B and -ΔEx3） are 
transcribed from the survivin gene, and both have been reported to have an anti-apoptosis 
function.  In addition, survivin expression level is related to the MIB-1 index and has been 
proposed as an index of tumor cell growth activity 23）.  Regarding apoptosis signals, p53 activated 
by DNA injury promotes the transcription of Bax and PUMA （p53 up-regulated modulator 
of apoptosis）, which control cytochrome c release by regulating mitochondrial membrane 
permeability.  Cytochrome c binds to Apaf-1 and forms an active complex with caspase 9, and 
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this complex activates caspase 3 and 7, executing apoptosis.  Survivin inhibits caspase 9 activity 
by binding to cofactor XIAP and thus acting as an anti-apoptosis factor.  It was recently 
reported that sensitivity to existing drugs was enhanced by the functional inhibition of survivin 
using siRNA and ribozyme24，25）.  In this study, there was no significant difference in survivin 
expression among Grades Ⅱ, Ⅲ, and Ⅳ tissues.  However, analysis within each grade uncovered 
a significant correlation between MIB-1- and survivin expression in Grade Ⅱ tumors.  These 
findings suggested that malignant brain tumors show a specific level of apoptosis resistance 
regardless of the histological grade, and the proliferative ability and resistance of tumor cells 
are associated only in low-malignant Grade Ⅱ brain tumors.  Apoptosis resistance in tumor 
cells with a low proliferative ability could reflect the numerous cells noted in the G0 phase. 
Since these cells are not actively progressing through the cell cycle, they do not respond to 
chemotherapy or show radiation sensitivity, and so do not undergo apoptosis.  
　Not all patients respond similarly to treatments of malignant brain tumors, and individualized 
treatment for patients is often necessary.  The induction of apoptosis in treatment-resistant CSC 
and survivin-positive cells may therefore be useful for the treatment of malignant tumors.  Since 
CSC are in the G0 phase, they must be induced to differentiate or undergo apoptosis.  The 
therapeutic outcomes may be further improved by investigating tumor resistance coupled with a 
combination of differentiation induction in resistant cells and increasing sensitivity to radiotherapy 
and chemotherapy.  Methods of killing CSC have been investigated, such as knocking out the 
self-replicating ability through inhibiting molecules necessary for self-replication and development 
of an antibody preparation against cell surface antigens specifically expressed by CSC, such as 
anti-CD44 antibody against HER2 for breast cancer 26）.  The addition of therapies targeting 
treatment-resistant cells to the standard protocol may improve survival rates in patients with 
malignant brain tumors.
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